Nasdaq GlobeNewswire

Oxford Immunotec Reports Fourth Quarter and Full Year 2017 Financial Results

Del
  • 2017 marks the 13th consecutive year of at least 20% year-over-year constant currency revenue growth
  • >25% pro forma organic growth for the year in tick-borne disease and other revenue
  • Balance sheet strengthened by December patent infringement settlement, which included a cash receipt of $27.5 million
  • Reduced royalty burden resulted in substantial gross margin improvement

OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced fourth quarter and full year 2017 financial results.

"While the year contained many ups and downs, in aggregate I am pleased with the substantial progress made throughout the Company in 2017" said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "2017 highlights included stronger-than-expected performance in Asia, a marked acceleration in Europe & ROW revenue growth, outperformance of our clinical tick-borne disease business, and the successful culmination of several strategically important multi-year initiatives on intellectual property, royalties and reimbursement."

By revenue type, total revenues were, in millions:

    Three Months Ended December 31,   Full Year Ended December 31,
    2017   2016   Percent 
Change
  2017   2016   Percent 
Change
                         
Product   $   9.7   $   9.3   5%   $   40.5   $   36.4   11%
Service       15.3     14.4   6%     62.6     49.6   26%
Total Revenue   $   25.0   $   23.7   6%   $   103.1   $   86.1   20%
                         

By indication, total revenues were, in millions:

    Three Months Ended December 31,   Full Year Ended December 31,
     2017    2016   Percent 
Change
   2017    2016   Percent 
Change
                         
Tuberculosis   $   21.0   $   20.4   3%   $   85.3   $   78.6   9%
Tick-Borne Disease and Other       4.0      3.3   24%        17.8      7.4   139%
Total Revenue   $   25.0   $   23.7   6%   $    103.1   $   86.1   20%
                         

By geography, total revenues were, in millions:

    Three Months Ended December 31,   Full Year Ended December 31,
            Percent Change           Percent Change
    2017   2016   As 
Reported
  Constant 
Currency (1)
  2017   2016   As 
Reported
  Constant 
Currency (1)
                                 
United States   $   15.6   $   14.7   6%   6%   $   64.1   $   49.5   30%   30%
Europe & ROW       2.2       1.7   27%   21%       8.1       7.0   16%   17%
Asia       7.2       7.3   -1%   2%       30.9       29.6   4%   6%
Total Revenue   $   25.0   $   23.7   6%   6%   $ 103.1   $   86.1   20%   20%
                                 

(1) Changes in revenue include the impact of changes in foreign currency exchange rates. We use the non-GAAP financial measure "constant currency basis" in our filings to show changes in our revenue without giving effect to period-to-period currency fluctuations. We consider the use of a period over period revenue comparison on a constant currency basis to be helpful to investors, as it provides a revenue growth measure free of positive or negative volatility due to currency fluctuations.

Fourth Quarter 2017 Financial Results

Revenue for the fourth quarter of 2017 was $25.0 million, representing 6% growth over the fourth quarter 2016 revenue of $23.7 million. Tuberculosis revenue for the fourth quarter of $21.0 million increased 3% over the prior year period. 

2017 fourth quarter product revenue was $9.7 million, representing a 5% increase from product revenue of $9.3 million in the fourth quarter of 2016. The increase in product revenue was primarily driven by strong growth in tuberculosis kit sales in Europe & ROW. Service revenue for the fourth quarter of 2017 was $15.3 million, up 6% from 2016 fourth quarter revenue of $14.4 million. The increase in service revenue was primarily driven by strong growth in our clinical tick-borne disease business, as well as tuberculosis volume increases in the United States and United Kingdom.

United States revenue was $15.6 million in the fourth quarter of 2017, representing 6% growth over revenue of $14.7 million in the prior year period. The increase was due to growth in our tuberculosis and tick-borne disease businesses.

Europe & ROW revenue was $2.2 million in the fourth quarter of 2017, representing a 27% increase compared to the fourth quarter of 2016. On a constant currency basis, Europe & ROW increased 21% versus the fourth quarter of 2016. The increase was primarily due to tuberculosis growth in the UK and continental European markets.

Asia revenue was $7.2 million in the fourth quarter of 2017, representing a 1% decrease compared to 2016 fourth quarter revenue of $7.3 million. On a constant currency basis, Asia grew 2% versus the fourth quarter of 2016.

Gross profit for the fourth quarter of 2017 was $14.5 million, an increase of $1.9 million over gross profit of $12.5 million in the same period of 2016. Gross margin for the fourth quarter of 2017 was 57.7%, an increase of 490 basis points from gross margin of 52.8% in the fourth quarter of 2016. The increase in gross margin was primarily the result of lower royalty expenses and favorable product mix.

Operating expenses were $28.1 million in the fourth quarter of 2017, an increase of $8.4 million compared to $19.7 million in the same period last year. The increase in operating expenses was largely due to the inclusion of a one-time non-cash impairment charge of $7.2 million to write-off certain intangible assets acquired in conjunction with the 2016 acquisition of Immunetics, as well as expenses related to our BLA submissions and patent litigation.

Net income for the fourth quarter of 2017 was $8.8 million, or $0.33 per share on a diluted basis, compared to a net loss $4.9 million, or $0.22 per share in the fourth quarter of 2016. Diluted net loss per share was based on 26,828,912 and 22,412,691 weighted average ordinary shares outstanding for the fourth quarters of 2017 and 2016, respectively. 

EBITDA for the fourth quarter of 2017 was $14.4 million compared to $(6.9) million in the fourth quarter of 2016. Adjusted EBITDA was $(4.0) million for the fourth quarter compared to $(5.2) million in the same period in 2016. Both EBITDA and Adjusted EBITDA are non-GAAP measures.

Full Year 2017 Financial Results

Revenue for the full year 2017 was $103.1 million, representing 20% growth over the full year 2016 revenue of $86.1 million.

2017 full year product revenue was $40.5 million representing an 11% increase from product revenue of $36.4 million in the full year 2016. The increase in product revenue was primarily driven by growth in TB volumes in Asia and Europe & ROW, as well as sales of tick-borne disease kits. Service revenue for the full year 2017 was $62.6 million, up 26% from $49.6 million in the full year 2016. The increase in service revenue was primarily driven by revenues from our tick-borne disease business, as well as tuberculosis volume increases in the United States and United Kingdom.

United States revenue was $64.1 million in the full year 2017 representing 30% growth compared to full year 2016 revenue of $49.5 million. The increase in United States revenue was primarily due to revenues from our tick-borne disease business.

Europe & ROW revenue was $8.1 million in the full year 2017 representing a 16% increase compared to full year 2016 revenue of $7.0 million. On a constant currency basis, Europe & ROW grew 17% versus the full year 2016. Asia revenue was $30.9 million in the full year 2017 representing 4% growth over full year 2016 revenue of $29.6 million. On a constant currency basis, Asia grew 6% versus the full year 2016. The increase was driven by continued growth in China and higher sales in South Korea.

Gross profit for the full year 2017 was $56.3 million, an increase of $9.7 million over gross profit of $46.6 million in the full year 2016. Gross margin was 54.7%, an increase of 60 basis points from a gross margin of 54.1% in the full year 2016. The full year gross margin performance reflects lower royalty expenses and an underlying improvement in tuberculosis cost of revenues. These margin benefits were partially offset by higher volumes in our tick-borne disease business, which carries lower gross margins, as well as some early infrastructure investments necessary to meet future growth.

Operating expenses were $109.9 million in the full year 2016, an increase of $37.4 million compared to $72.6 million in the full year 2016. The increase in operating expenses was due to the inclusion of a full year of operating costs from both Imugen and Immunetics, expenses related to our BLA submissions and patent litigation, the inclusion of a charge related to the SSI settlement, and the inclusion of non-cash impairment charges of $18.3 million to write-off certain intangible assets acquired in conjunction with the 2016 acquisitions of Imugen and Immunetics.

Net loss for the full year 2017 was $32.9 million, or $1.38 per share, compared to a loss of $22.3 million, or $1.00 per share for the full year 2016. Net loss per share was based on 23,757,902 and 22,353,713 weighted average ordinary shares outstanding for the full years 2017 and 2016, respectively. 

EBITDA for the full year 2017 was $(23.9) million compared to $(22.2) million for the full year 2016. Adjusted EBITDA was $(20.0) million for the full year 2017 compared to $(18.5) million for the full year 2016. Both EBITDA and Adjusted EBITDA are non-GAAP measures.

Cash and cash equivalents were $90.3 million as of December 31, 2017. This compares to cash and cash equivalents of $59.1 million as of December 31, 2016.

Business Outlook

For full year 2018, the Company expects revenue of between $112 and $118 million, representing 9% - 15% year-over-year growth as reported.

Conference Call

Oxford Immunotec will host a conference call on Tuesday, February 27, 2018 at 8:00 a.m. Eastern Time to review fourth quarter and full year 2017 financial results. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 6949857, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com.  The replay will be available on the Company's website for approximately 60 days.  

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions.  The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection.  The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China.  The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass.  Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.  Immunetics is a trademark of Immunetics, Inc.

This release contains forward-looking statements that involve risks and uncertainties, including statements about our anticipated plans, objectives, intentions, including effects on future financial and operating results, prospects for sales of our products and other statements that are not historical facts. The forward-looking statements in this release are based on current expectations, assumptions and data available as of the date of this release and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: decisions by regulatory authorities, hospitals and other health care institutions, laboratories, physicians, patients and third party payers that could affect the Company's business and prospects; as well as our ability to expeditiously and successfully expand our sales and distribution networks. The risks included above are not exhaustive. Other factors that could adversely affect our business and prospects are described under the "Risk Factors" section in our filings with the Securities and Exchange Commission ("SEC"). Our filings are available for free by visiting the investor section of our website, www.oxfordimmunotec.com, or the SEC's website, www.sec.gov.

Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.

CONTACT:

For Media and Investor Inquiries: 
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
kkoski@oxfordimmunotec.com

Oxford Immunotec Global PLC
Condensed consolidated statements of operations
(unaudited)

    Three months ended December 31,   Year ended December 31,
(in thousands, except share and per share data)   2017   2016   2017   2016
Revenue                
Product   $   9,714      $   9,286      $   40,522      $   36,430   
Service       15,312          14,419          62,558          49,648   
Total revenue       25,026          23,705          103,080          86,078   
Cost of revenue                
Product       2,428          3,535          13,794          13,956   
Service       8,146          7,663          32,937          25,516   
Total cost of revenue       10,574          11,198          46,731          39,472   
Gross profit       14,452          12,507        56,349          46,606   
Operating expenses:                
Research and development       4,481          4,044          16,701          13,881   
Sales and marketing       8,842          8,299          38,016          34,964   
General and administrative       7,359          6,981          30,366          23,181   
Change in fair value of contingent purchase price consideration       -          (1,380 )       (3,475 )       (1,208 )
Intangible assets impairment charges       7,236          1,765          18,300          1,765   
Settlement expense       197          -          10,028          -   
Total operating expenses       28,115          19,709          109,936          72,583   
Loss from operations       (13,663 )       (7,202 )       (53,587 )       (25,977 )
Other income (expense):                
Interest expense, net       (694 )       (776 )       (3,105 )       (864 )
Foreign exchange (losses) gains       (573 )       (343 )       (1,850 )       1,364   
Other income (expense)       53          (403 )       (209 )       (646 )
Litigation settlement income       27,500          -          27,500          -   
Income (loss) before income taxes       12,623          (8,724 )       (31,251 )       (26,123 )
Income tax (expense) benefit       (3,823 )       3,866          (1,634 )       3,774   
Net income (loss)    $   8,800      $   (4,858 )   $   (32,885 )   $   (22,349 )
                 
Net income (loss) per ordinary share:                
Basic   $   0.34     $   (0.22 )   $   (1.38 )   $   (1.00 )
Diluted   $   0.33     $   (0.22 )   $   (1.38 )   $   (1.00 )
                 
Weighted-average shares used to compute net income (loss) per ordinary share:                
Basic       25,532,152          22,412,691          23,757,902          22,353,713   
Diluted       26,828,912          22,412,691          23,757,902          22,353,713   
                 

Reconciliation of net loss to Adjusted EBITDA (1)
(unaudited)

    Three months ended December 31,   Year ended December 31,
(in thousands)   2017   2016   2017   2016
Net loss   $   8,800      $   (4,858 )   $   (32,885 )   $   (22,349 )
Income tax (benefit) expense       3,823          (3,866 )       1,634          (3,774 )
Interest expense, net       553          776         2,535          864   
Depreciation and amortization       1,125          1,027          4,240          3,094   
Accretion and amortization of loan fees       141          -          570          -   
EBITDA       14,442          (6,921 )     (23,906 )       (22,165 )
                 
Reconciling items:                
Share-based compensation expense       1,598          1,192          5,864          5,019   
Unrealized exchange (gains) losses       72          110          686          (1,880 )
Change in fair value of contingent purchase price consideration       -          (1,380 )       (3,475 )       (1,208 )
Intangible asset impairment charge       7,236          1,765          18,300          1,765   
Settlement expense       197          -          10,028          -   
Litigation settlement income       (27,500 )       -          (27,500 )       -   
Adjusted EBITDA   $   (3,955 )   $   (5,234 )   $   (20,003 )   $   (18,469 )
                 

(1)  EBITDA and Adjusted EBITDA are non-GAAP measures that we calculate as net loss, adjusted for the impact of earnings or charges resulting from matters that we consider not to be indicative of our ongoing operations. We believe that these measures provide useful information to investors in understanding and evaluating our operating results in the same manner as our management and Board of Directors. Our presentation of these measures is not made in accordance with U.S. GAAP, and our computation of these measures may vary from others in the industry. Our use of these measures has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under U.S. GAAP.

The above table presents a reconciliation of net loss, the most comparable U.S. GAAP measure, to EBITDA and Adjusted EBITDA for each of the periods indicated.

Oxford Immunotec Global PLC
Condensed consolidated balance sheets
(unaudited)

    December 31,
(in thousands, except share and per share data)   2017   2016
Assets        
Current assets:        
Cash and cash equivalents   $   90,332      $   59,110   
Accounts receivable, net       16,981          13,265   
Inventory, net       10,142          7,437   
Prepaid expenses and other assets       3,027          2,390   
Total current assets       120,482          82,202   
Restricted cash, non-current       200          200   
Property and equipment, net       9,067          7,793   
In-process research and development       -          16,170   
Goodwill       3,967          3,822   
Other intangible assets, net       7,849          11,017   
Deferred tax asset       2,486          2,630   
Other assets       185          178   
Total assets   $   144,236      $   124,012   
         
Liabilities and shareholders' equity        
Current liabilities:        
Accounts payable   $   6,842      $   3,201   
Accrued liabilities       11,134          14,282   
Settlement liability       4,342          -   
Contingent purchase price consideration       -          882   
Deferred income       36          41   
Current portion of loans payable       91          84   
Total current liabilities       22,445          18,490   
Long-term portion of loans payable       29,904          29,601   
Settlement liability       3,894          -   
Contingent purchase price consideration       -          2,593   
Other liabilities       364          364   
Total liabilities       56,607          51,048   
         
Shareholders' equity:        
Ordinary shares, £0.006705 nominal value; 36,183,293 shares authorized at December 31, 
2017 and December 31, 2016, and 25,661,634 and 22,635,431 shares issued and 
outstanding at December 31, 2017 and 2016, respectively
      269          243   
Additional paid-in capital       294,613          249,128   
Accumulated deficit       (201,541 )       (168,656 )
Accumulated other comprehensive loss       (5,712 )       (7,751 )
Total shareholders' equity       87,629          72,964   
Total liabilities and shareholders' equity   $   144,236      $   124,012   
         



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Bombardier Delivers First 90-seat Q400 Aircraft to SpiceJet21.9.2018 16:00Pressemelding

SpiceJet becomes the first airline to take advantage of the Q400 aircraft’s increased profit potential TORONTO, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft today announced the delivery of its first 90-seat Q400 aircraft. The aircraft was handed over to India’s SpiceJet Limited (“SpiceJet”) the launch operator for the extra-capacity, 90-seat aircraft. “We are excited to induct the 90-seat Q400 aircraft into our fleet,” said Ajay Singh, Chairman and Managing Director, SpiceJet. “The additional seats and performance improvements will result in substantial reduction in unit costs and also we will enable us to address our market needs in the regional space.” “The delivery of the first 90-seat Q400 aircraft showcases the commitment of Bombardier’s Q Series turboprop program to respond to customer requirements as they address traffic growth in regional markets,” said Todd Young, Head of the Q Series Aircraft Program, Bombardier Commercial Aircraft. “I thank and congratul

Service Providers Speed Deployment, Reduce Costs with Patton Cloud Edge Orchestration Service20.9.2018 22:16Pressemelding

Now, Telecom and UCaaS service providers can easily provision, manage, monitor, secure, alert, troubleshoot, analyze, and optimize services on the customer premise GAITHERSBURG, Md., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Patton Electronics—US-manufacturer of UC, cloud, and IoT-enabling solutions for carrier, enterprise, and industrial networks—has launched the new Patton Cloud service for carriers and service providers that deliver All-IP and hybrid voice-and-data services to business subscribers. Patton Cloud delivers a low-cost, easy-to-use, web-based edge-orchestration service that delivers a superior user experience. It offers remote touchless provisioning, monitoring, and troubleshooting—as well as security and alerting tools that reduce service turn-up costs, trouble tickets, and subscriber attrition. The Patton Cloud service offers quality-control mechanisms including pro-active monitoring and troubleshooting—combined with feature-license distribution pools for managing value-added

Inspirata Promotes Top Executives to Expanded Roles in Digital Pathology20.9.2018 21:12Pressemelding

Inspirata Founder and Executive Vice President, Mark Lloyd, is taking on an expanded role overseeing product management, and Inspirata Senior Vice President, Andrew Chomos, has been appointed to General Manager, Digital Pathology, overseeing the Center of Excellence in Pittsburgh along with all North America sales and customer support efforts. Tampa, FL, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced today that two of its executives have taken on expanded roles in the company. The two are Inspirata Executive Vice President and Founder, Mark Lloyd, and Senior Vice President and General Manager, Digital Pathology, Andrew Chomos. Dr. Lloyd has accepted the expansion of his role to include product management for Digital Pathology. He is former cancer researcher at both Lombardi Cancer and Moffitt Cancer Center and is Inspirata’s foremost subject matter expert and thought leader on digital pathology and image

Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections20.9.2018 19:08Pressemelding

– Broad Product Label for Treatment of Complicated Intra-Abdominal Infections – – Phased Commercial Launch Expected in the First Half of 2019 – WATERTOWN, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that the European Commission (EC) has adopted the Decision granting marketing authorisation for XERAVA (eravacycline) for injection for the treatment of complicated intra-abdominal infections (cIAI) in adults in the European Union. In clinical trials, XERAVA was well-tolerated and achieved high clinical cure rates in patients with cIAI, demonstrating statistical non-inferiority to two widely used comparators – ertapenem and meropenem. “The European approval of XERAVA, right after our recently announced FDA approval, marks our second significant regulatory approval within one month

UPDATE— Taconic Biosciences Becomes the First Animal Model Provider on General Services Administration Contract Schedule20.9.2018 18:07Pressemelding

RENSSELAER, N.Y., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces a new relationship with Government Scientific Source (GSS). GSS is a leading dedicated distributor of laboratory equipment to federal, state, and local governments on contract with the GSA (General Services Administration). By having Taconic’s products available via GSS, they can now be accessed by all federal agencies, including but not limited to the National Institutes of Health and the Department of Defense. Taconic is the only animal model provider affiliated with GSS and the only animal model provider available on GSA Contract. “An important component of providing customers with the best animal model solutions is access to key resources. Through this exciting new relationship with GSS, Taconic can now easily connect with scientists doing some of the most valuable research in the world and provide them with high quality sol

Digital Transformation is Not a One-Off — It’s About the Digital Journey20.9.2018 17:44Pressemelding

SoftServe study confirms four digital journey states with 71 percent of enterprises reporting early stages of adoption AUSTIN, Texas, Sept. 20, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, today released the results of its market research study that examines how enterprises are responding to the digital economy. The research found that 71 percent of the respondents in the United States and the European Union are in the early stages—Reveal and Transform—of four unique states across the Enterprise Digital Journey. For an in-depth analysis and the full results, read The Enterprise Digital Journey white paper. With fierce competition in today’s global landscape, leveraging cutting-edge technology and deploying new business models is not a one-off pursuit, but rather a continuous process of iteration and refinement. Companies should stop referring to Digital Transformation and instead plan for a continuous Digital Journey. “The term Digital Transfo

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom